Drug Trial Radar · NCT07901595
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
147
Planned (sponsor's estimate)
Start
Nov 1, 2026
Primary completion
Nov 1, 2027
Study completion Jan 31, 2028
Sponsor
- Lead sponsor
- Paulex Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1/2 randomized study of oral doses of PAL-119 in healthy volunteers and participants with diabetes.
Conditions
- Healthy Volunteers and Diabetes Participants
Interventions
PAL-119Drug
Small synthetic molecule
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 Part 1: Safety and tolerability of PAL-119 in healthy volunteersTime frame: 8 days
- Phase 1 Part 2: Safety and tolerability of PAL-119 in healthy volunteersTime frame: 17 days
- Phase 1 Part 3: Safety and tolerability of PAL-119 in healthy volunteersTime frame: 8 days
- Phase 2 Part 4: Safety and tolerability of PAL-119 in adult participants with Type 2 diabetesTime frame: 17 weeks
- Phase 2 Part 4: Incidence and severity of hypoglycemic episodes in adult participants with Type 2 diabetesTime frame: 17 weeks
- Phase 2 Part 5: Safety and tolerability of PAL-119 in adult participants with Type 1 diabetesTime frame: 17 weeks
- Phase 2 Part 5: Incidence and severity of hypoglycemic episodes in adult participants with Type 1 diabetesTime frame: 17 weeks
- Phase 2 Part 5: Incidence and severity of diabetic ketoacidosis and episodes of hyperglycemia with ketonemia not meeting diagnostic criteria for diabetic ketoacidosis in adult participants with Type 1 diabetesTime frame: 17 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.